Education
About Us
Working with TipRanks
Follow Us
Kindstar Globalgene Technology, Inc. (HK:9960)
:9960
9960 Stock Chart & Stats
HK$1.17
HK$0.05(4.55%)
At close: 4:00 PM EST
HK$1.17
HK$0.05(4.55%)
Day’s Range― - ―
52-Week RangeHK$1.03 - HK$1.75
Previous CloseN/A
Volume114.00K
Average Volume (3M)956.95K
Market Cap
HK$1.25B
Enterprise ValueHK$826.58M
Total Cash (Recent Filing)HK$1.61B
Total Debt (Recent Filing)HK$471.06M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.02%
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,041,309,900
10 Day Avg. Volume603,200
30 Day Avg. Volume956,950
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.38
Price to Sales (P/S)1.13
P/FCF Ratio-5.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength And Low LeverageA high equity ratio and minimal debt provide durable financial resilience, allowing Kindstar to absorb revenue shocks, fund operations without heavy interest burdens, and retain strategic optionality for partnerships or targeted investments over the next several quarters.
Specialized Diagnostics FranchiseConcentration in molecular diagnostics and medical genetics positions the company in high-barrier, high-value testing markets. Structural tailwinds—precision medicine, aging populations, and hospital partnerships—support stable demand and pricing power over a multi-quarter horizon.
Positive EBITDA In 2023Positive EBITDA indicates core operations generate cash before noncash items and financing costs, showing underlying service profitability. This provides a foundation to convert to operating profits if management tightens costs or scales volumes, improving long-term cash conversion.
Bears Say
Declining Revenue And Negative MarginsFalling top-line combined with persistent negative EBIT and net margins undermines sustainable growth and reinvestment capacity. Without revenue stabilization or margin improvement, the firm may struggle to finance expansion, retain clinical partners, and support long-term R&D or service upgrades.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow signal weak cash generation from core services, limiting ability to fund capex or strategic initiatives internally. Over months, this raises reliance on external funding, increasing financing risk and reducing strategic flexibility.
Erosion Of Shareholders' EquityDeclining equity reduces the balance-sheet cushion against losses and heightens vulnerability to shocks. Over 2–6 months, continued erosion can constrain borrowing capacity, raise credit costs, and force dilutive capital raises or cost-cutting that impair long-term competitiveness.
Kindstar Globalgene Technology, Inc. News
9960 FAQ
What was Kindstar Globalgene Technology, Inc.’s price range in the past 12 months?
Kindstar Globalgene Technology, Inc. lowest stock price was HK$1.03 and its highest was HK$1.75 in the past 12 months.
What is Kindstar Globalgene Technology, Inc.’s market cap?
Kindstar Globalgene Technology, Inc.’s market cap is HK$1.25B.
When is Kindstar Globalgene Technology, Inc.’s upcoming earnings report date?
Kindstar Globalgene Technology, Inc.’s upcoming earnings report date is Apr 01, 2026 which is in 36 days.
How were Kindstar Globalgene Technology, Inc.’s earnings last quarter?
Kindstar Globalgene Technology, Inc. released its earnings results on Aug 28, 2025. The company reported -HK$0.041 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.041.
Is Kindstar Globalgene Technology, Inc. overvalued?
According to Wall Street analysts Kindstar Globalgene Technology, Inc.’s price is currently Overvalued.
Does Kindstar Globalgene Technology, Inc. pay dividends?
Kindstar Globalgene Technology, Inc. pays a Annually dividend of HK$0.024 which represents an annual dividend yield of 2.02%. See more information on Kindstar Globalgene Technology, Inc. dividends here
What is Kindstar Globalgene Technology, Inc.’s EPS estimate?
Kindstar Globalgene Technology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kindstar Globalgene Technology, Inc. have?
Kindstar Globalgene Technology, Inc. has 1,041,309,900 shares outstanding.
What happened to Kindstar Globalgene Technology, Inc.’s price movement after its last earnings report?
Kindstar Globalgene Technology, Inc. reported an EPS of -HK$0.041 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.069%.
Which hedge fund is a major shareholder of Kindstar Globalgene Technology, Inc.?
Currently, no hedge funds are holding shares in HK:9960
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kindstar Globalgene Technology, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.75%
12-Months-Change
Fundamentals
Return on Equity
-3.59%
Trailing 12-Months
Asset Growth
3.95%
Trailing 12-Months
Company Description
Kindstar Globalgene Technology, Inc.
Kindstar Global (Beijing) Technology, Inc. provides medical esoteric testing services to hospitals in China. Its services include medical research, drug trial, and translational medicine research services for physicians, medical science and technology institutions, specialty and general hospitals, and pharmaceutical companies. The company's lab platforms comprise flow cytometry, cytogenetic, medical genomics, molecular biology, hematopathology, mass spectrum, pathology, clinical immunology, microbiology, and scientific research laboratories. It provides tests in blood, tumor, and genetics; and cardiovascular, cerebrovascular, infectious, and autoimmune diseases, as well as in internal medicine, surgery, gynecology, pediatrics, and other specialties. The company was founded in 2003 and is headquartered in in Wuhan, China.
Technical Analysis
New Century Healthcare Holding Co. Ltd.
―
Rici Healthcare Holdings Ltd.
―
Guangdong Kanghua Healthcare Co., Ltd. Class H
―
Hospital Corporation of China Ltd
―
Town Health International Medical Group Ltd.
―
Options Prices
Currently, No data available
---